WO2000006764A1 - Gastrointestinal bacterial antibody factories - Google Patents
Gastrointestinal bacterial antibody factories Download PDFInfo
- Publication number
- WO2000006764A1 WO2000006764A1 PCT/US1999/017296 US9917296W WO0006764A1 WO 2000006764 A1 WO2000006764 A1 WO 2000006764A1 US 9917296 W US9917296 W US 9917296W WO 0006764 A1 WO0006764 A1 WO 0006764A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- pathogen
- antibodies
- antibody
- probiotic
- Prior art date
Links
- 230000002496 gastric effect Effects 0.000 title description 34
- 230000001580 bacterial effect Effects 0.000 title description 15
- 244000052769 pathogen Species 0.000 claims abstract description 86
- 241000894006 Bacteria Species 0.000 claims abstract description 60
- 239000006041 probiotic Substances 0.000 claims abstract description 56
- 230000000529 probiotic effect Effects 0.000 claims abstract description 56
- 235000018291 probiotics Nutrition 0.000 claims abstract description 56
- 230000001717 pathogenic effect Effects 0.000 claims abstract description 54
- 239000000203 mixture Substances 0.000 claims abstract description 45
- 238000000034 method Methods 0.000 claims abstract description 28
- 241000588724 Escherichia coli Species 0.000 claims description 34
- 241000702670 Rotavirus Species 0.000 claims description 33
- 241001465754 Metazoa Species 0.000 claims description 22
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 21
- 230000014509 gene expression Effects 0.000 claims description 17
- 241000700605 Viruses Species 0.000 claims description 11
- 241000894007 species Species 0.000 claims description 11
- 230000001332 colony forming effect Effects 0.000 claims description 9
- 230000028993 immune response Effects 0.000 claims description 9
- 230000037396 body weight Effects 0.000 claims description 8
- 241000607142 Salmonella Species 0.000 claims description 7
- 229940023064 escherichia coli Drugs 0.000 claims description 7
- 244000005700 microbiome Species 0.000 claims description 7
- 241000186606 Lactobacillus gasseri Species 0.000 claims description 6
- 230000000153 supplemental effect Effects 0.000 claims description 5
- 244000199866 Lactobacillus casei Species 0.000 claims description 4
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 4
- 239000005913 Maltodextrin Substances 0.000 claims description 4
- 229920002774 Maltodextrin Polymers 0.000 claims description 4
- 230000000688 enterotoxigenic effect Effects 0.000 claims description 4
- 229940035034 maltodextrin Drugs 0.000 claims description 4
- 241000186000 Bifidobacterium Species 0.000 claims description 3
- 206010008631 Cholera Diseases 0.000 claims description 3
- 241000711573 Coronaviridae Species 0.000 claims description 3
- 241000709687 Coxsackievirus Species 0.000 claims description 3
- 241000205707 Cystoisospora belli Species 0.000 claims description 3
- 241000709661 Enterovirus Species 0.000 claims description 3
- 241000991587 Enterovirus C Species 0.000 claims description 3
- 241001302654 Escherichia coli Nissle 1917 Species 0.000 claims description 3
- 241000224467 Giardia intestinalis Species 0.000 claims description 3
- 241000709721 Hepatovirus A Species 0.000 claims description 3
- 206010023076 Isosporiasis Diseases 0.000 claims description 3
- 241000186840 Lactobacillus fermentum Species 0.000 claims description 3
- 241000186605 Lactobacillus paracasei Species 0.000 claims description 3
- 241000577554 Lactobacillus zeae Species 0.000 claims description 3
- 241000194036 Lactococcus Species 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 241000702244 Orthoreovirus Species 0.000 claims description 3
- 241000607768 Shigella Species 0.000 claims description 3
- 241000244174 Strongyloides Species 0.000 claims description 3
- 239000002274 desiccant Substances 0.000 claims description 3
- 244000000036 gastrointestinal pathogen Species 0.000 claims description 3
- 229940085435 giardia lamblia Drugs 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 230000001502 supplementing effect Effects 0.000 claims description 3
- 241000701161 unidentified adenovirus Species 0.000 claims description 3
- 241000589876 Campylobacter Species 0.000 claims description 2
- 241000224431 Entamoeba Species 0.000 claims description 2
- 241000223935 Cryptosporidium Species 0.000 claims 1
- 241000607734 Yersinia <bacteria> Species 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 210000000987 immune system Anatomy 0.000 abstract description 6
- 230000003053 immunization Effects 0.000 abstract description 4
- 230000001010 compromised effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 46
- 108090000623 proteins and genes Proteins 0.000 description 33
- 208000015181 infectious disease Diseases 0.000 description 22
- 108020004414 DNA Proteins 0.000 description 17
- 239000013612 plasmid Substances 0.000 description 17
- 241000282412 Homo Species 0.000 description 16
- 239000000427 antigen Substances 0.000 description 16
- 108091007433 antigens Proteins 0.000 description 16
- 102000036639 antigens Human genes 0.000 description 16
- 235000013305 food Nutrition 0.000 description 13
- 238000013459 approach Methods 0.000 description 12
- 238000004520 electroporation Methods 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 239000002775 capsule Substances 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 230000003472 neutralizing effect Effects 0.000 description 9
- 230000003248 secreting effect Effects 0.000 description 9
- 241000186660 Lactobacillus Species 0.000 description 8
- 230000002953 anti-rotaviral effect Effects 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 238000010367 cloning Methods 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 230000009466 transformation Effects 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 7
- 239000002245 particle Substances 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000012634 fragment Substances 0.000 description 5
- 244000144972 livestock Species 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 244000057717 Streptococcus lactis Species 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 241000607626 Vibrio cholerae Species 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000004091 panning Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 206010017964 Gastrointestinal infection Diseases 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 241000186779 Listeria monocytogenes Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 101100370002 Mus musculus Tnfsf14 gene Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 206010067470 Rotavirus infection Diseases 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 235000014897 Streptococcus lactis Nutrition 0.000 description 2
- 241000607447 Yersinia enterocolitica Species 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 210000003022 colostrum Anatomy 0.000 description 2
- 235000021277 colostrum Nutrition 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000000741 diarrhetic effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000009429 distress Effects 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 235000013350 formula milk Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000013384 milk substitute Nutrition 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000009967 tasteless effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 229940098232 yersinia enterocolitica Drugs 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 101710192393 Attachment protein G3P Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000224432 Entamoeba histolytica Species 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 101710179596 Gene 3 protein Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000430519 Human rhinovirus sp. Species 0.000 description 1
- 241000724191 Lactobacillus phage mv4 Species 0.000 description 1
- 108091036060 Linker DNA Proteins 0.000 description 1
- 101710105759 Major outer membrane porin Proteins 0.000 description 1
- 101710164702 Major outer membrane protein Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001135960 Murine rotavirus Species 0.000 description 1
- 206010061308 Neonatal infection Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000150264 Puumala orthohantavirus Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000002223 anti-pathogen Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 244000275904 brauner Senf Species 0.000 description 1
- 244000144987 brood Species 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229940015062 campylobacter jejuni Drugs 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000003021 clonogenic effect Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- -1 elixirs Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229940007078 entamoeba histolytica Drugs 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 108700010839 phage proteins Proteins 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to the field of genetically engineered bacteria for therapeutic and prophylactic use.
- the invention provides recombinant probiotic bacteria expressing antibodies to common gastrointestinal pathogens, and methods for their use in disease treatment and prevention.
- Immunosuppression in adults also increases vulnerability to pathogenic organisms to which the individual normally would be able to mount an immune defense.
- pathogenic organisms include pathogenic Escherl chla coli , Cryptosporidi um, Salmonella, Vibri o chol era, Li steria monocytogenes and Heli cobacter pyl ori (associated with ulcer development) , among others.
- healthy adults exposed to an unusual pathogen or a large dose of pathogen e.g., Cryptosporidi um in contaminated drinking water or Salmonella-contaminated food and milk
- One approach is to immunize (vaccinate) pregnant mothers using antigens associated with the pathogenic organism (e.g., pathogenic strains of Escheri chia coli ) .
- the objective is to stimulate production of antibodies against the pathogen in the mother' s colostrum, the milk that is fed to neonates in the first day or two postpartum.
- the antibody consumed by a neonate of some species may be retained for a period of time (i.e., absorbed into the blood and circulated) , providing some immune coverage against subsequent exposure to the pathogen.
- none of the colostrum antibodies are retained and so this approach is not effective.
- a second approach has been to immunize the neonate against pathogens using antigens associated with the pathogenic organisms.
- the oral administration of live heterologous and homologous rotavirus protected neonate and adult mice against a virulent murine rotavirus challenge (Feng et al . , 1994, J. Virology 68:7766-7773; Burns et al . , 1995, Virology 207:143-153).
- this approach has met with very limited success. In human neonates in particular the immune system is only slightly functional, and so humans are unlikely to be benefitted by neonate immunization.
- a third approach has been to administer a bolus, usually by nasal injection, of antibody or semi- purified antisera, directed against the pathogen of interest, to the neonate animal. If the concentration of antibody is high enough on the GI mucosal surface, and the injections are repeated frequently enough to keep the antibody concentration high, then this procedure would afford the animal a means of protection against GI pathogens.
- this approach is neither cost- feasible nor time/personnel- feasible in an animal production facility of any significant size, inasmuch as it requires repeated handling of individual neonates, as well as multiple administrations of purified antibodies or serum, which can be expensive.
- compositions and methods for supplementing or replacing an immune response against selected pathogens in individuals requiring such treatment are directed toward newborn infants, either animals or humans, or to immunosuppressed or immunodeficient adults, or to healthy individuals acutely exposed to a bolus of GI pathogen.
- the compositions of the invention comprise probiotic microorganisms which have been genetically modified to express recombinant antibodies (rAB) directed against selected pathogenic organisms.
- the probiotic microorganisms are GI tract-colonizing or -associated bacteria, such as Lactococcus, Bifidobacteria, Eubacteria, non-pathogenic strains of Escheri chia coli , E.
- Lactobacill us such as L . casei , L . plantarum, L . paracasei , L . acidophil us, L . fermentum, L . zeae and L . gasseri .
- the pathogenic organisms are GI pathogens, such as rotavirus, caliciviruses, reoviruses, coronaviruses, enteroviruses, adenoviruses, Norwalk-type viruses, enterotoxigenic Escheri chia coli , Campyl obacter j ej uni , Yersinia enter ocoli tica, Cryptosporidi um spp., Giardia lamblia, Entamoeba histolyti ca, Heli obacter pyl ori , Isospora belli , Cl ostridi um spp .
- GI pathogens such as rotavirus, caliciviruses, reoviruses, coronaviruses, enteroviruses, adenoviruses, Norwalk-type viruses, enterotoxigenic Escheri chia coli , Campyl obacter j ej uni , Yers
- the antibodies expressed by the probiotic bacteria are adapted for expression in bacteria. Though any one bacterial cell produces only a single species of recombinant antibody, multiple clones of producing bacteria can be mixed to provide probiotic populations that produce recombinant antibodies against multiple pathogens at the same time.
- the probiotic bacteria may express a mixed population of antibodies immunologically specific to one pathogen, or to more than one pathogen.
- the probiotic organism is expressing a rotavirus-neutralizing antibody.
- the composition of the invention further comprises lactose, maltodextrin and/or a desiccant.
- the invention is practiced by feeding the antibody-expressing probiotic organisms to an animal or human in need of such treatment.
- the organisms colonize or otherwise become associated with the GI tract of the individual, whereupon they grow and multiply, continuing to produce and secrete anti-pathogen antibodies.
- a steady-state immune condition with respect to the selected pathogens is created in the GI tract of the individual, who is thereby protected from infection by the pathogen (s), even though the individual is unable to generate its own immune response.
- the individual requiring this treatment is a neonate, immunosupressed or immunodeficient adult, or a healthy individual acutely exposed to a bolus of one or more pathogens.
- a supplemental bolus of antibodies immunologically specific to at least one pathogen is administered with the antibody-expressing probiotic organism.
- the antibody-expressing probiotic organism is administered orally to a neonate in a bolus comprising up to 40 X 10 9 colony forming units (cfus), two times a day, for up to eight weeks of probiotic bacteria, and may additionally comprise up to 25 mg/kg body weight/day of at least one antibody immunologically specific to at least one pathogen.
- the antibody-expressing probiotic organism is administered orally to an adult in a bolus comprising up to 80 X 10 9 colony forming units, three times a day, for ten days or until the external threat of the pathogen is removed.
- the bolus may additionally comprise up to 25 mg/kg body weight/day of at least one antibody immunologically specific to at least one pathogen.
- FIG. 1 DNA sequence analysis of the ⁇ 750 base pair Sfil-Notl insert in the pCANTAB 5E cloning/expression vector (Clone 11) (SEQ ID NO:l) .
- the open reading frame within the insert contains the mouse variable heavy chain (V H ) and variable light chain (V L ) domains which are found in the monoclonal antibody secreted by the M159 hybridoma.
- the open reading frame also contains the 13 amino acid E tag domain that enables immunodetection and immunoaffinity purification of the rAb molecule.
- the Sfil and ⁇ Votl sites the define the rAb insert region, the V H domain showing 97-99% sequence identity to other mouse heavy chain genes, the linker region, the V L domain showing 95-99% sequence identity to other mouse light chain genes and the 13 amino acids E tag domain are all indicated.
- FIG. 1 DNA sequence analysis of the ⁇ 750 base pair Sfil-Notl insert in the pCANTAB 5E cloning/expression vector (Clone 22) (SEQ ID NO:2) .
- the sequence is identical to that found in Clone 11 except for two codons within the linker region, and two codons within the V H region that could provide minor differences in recognition and binding affinity for the encoded rAb.
- the Sfil and Notl sites the define the rAb insert region, the V H domain showing 97-99% sequence identity to other mouse heavy chain genes, the linker region, the V L domain showing 95-99% sequence identity to other mouse light chain genes and the 13 amino acids E tag domain are all indicated.
- Figure 3 DNA sequence analysis of the ⁇ 750 base pair Sfil-Notl insert in the pCANTAB 5E cloning/expression vector (Clone 22) (SEQ ID NO:2) .
- the sequence is identical to that found in Clone 11 except for two codons within the linker region, and two codons within
- Figure 5 The percent of neonate mice with diarrhea after a gastric bolus containing 0 ⁇ g, 25 ⁇ g, 8 ⁇ g and 1 ⁇ g of M159 rotavirus monoclonal antibody followed by an oral rotavirus challenge dose (10 7 pfu) .
- Figure 6 The percent of neonate mice with diarrhea at three days after a gastric bolus containing 25 ⁇ g of M159 rotavirus antibody followed by an oral rotavirus challenge dose O h, 8 h, 16 h and 25 h later.
- the control treatment consisted of a gastric bolus without M159 rotavirus antibody with an oral rotavirus challenge dose 25 h later.
- This invention is applicable to the prevention or control of disease caused by any pathogen against which a gastrointestinal immune response is effective. It is particularly applicable to GI pathogens, but can also provide a measure of protection (i.e., a first line of defense) against ingested pathogens whose natural target is not the GI tract.
- a measure of protection i.e., a first line of defense
- GI pathogens contemplated as targets for practice of the present invention include, but are not limited to: rotavirus, caliciviruses, reoviruses, coronaviruses, enteroviruses, adenoviruses, Norwalk-type viruses, enterotoxigenic Escheri chia coli , Campyl obacter jej uni , Yersinia enterocoli tica, Cl ostridi um spp., Vibrio chol era, Cryptosporidi um spp., Giardia lamblia, Entamoeba histolytica, Heliobacter pylori , and Isospora belli .
- Non-GI pathogens that enter the body through the GI tract contemplated as targets for practice of the present invention include, but are not limited to coxsackieviruses, poliovirus, hepatitis A virus, Salmonella and Shigella spp., Listeria monocytogenes and strongyloides .
- Neutralizing antibodies against one or more selected pathogens can be produced using any standard methodology. They can be generated against any antigenic determinant of the pathogen, including the intact pathogen, specific surface antigens of the pathogen, epitopes of those surface antigens, or any other portion of the organism capable of eliciting an immune response. In a preferred embodiment, recombinant antibodies from a particular species are used to immunize the same species.
- monoclonal antibodies immunologically specific for a particular antigen of the pathogen are produced according to standard methodologies. Some such antibodies are already known and available. For instance, Example 1 describes a neutralizing monoclonal antibody against rotavirus serotype G3. In addition, a hybridoma is available from the American Type Culture collection (ATCC Accession No. HB 8178), which secretes a monoclonal antibody against the K99 pilus protein found on enterotoxigenic strains of E. coli . The advantage of using a monoclonal antibody is that it is directed to a single antigen or epitope that can be pre-screened as w neutralizing" , i.e.
- a mixed population of monoclonal antibodies, or a population of polyclonal antibodies may also be used in the invention.
- spleens from immunized mice may be harvested and used to clone a mixed population of antibodies against the antigen used for immunization.
- the advantage of this approach is that the mixed antibody population targets a diverse array of epitopes on the pathogen, which will be able to neutralize the pathogen at different sites within the physiologically changing conditions of the mammalian or avian GI tract.
- recombinant antibodies suitable for use with the invention may be synthetic mutants.
- One or more recombinant antibodies specific to a site on a selected pathogen may be isolated by starting with a library of recombinant antibodies.
- this antibody library the three short domains within the variable region of the heavy chain (residues 31-33, 50-54, 95-98) and the three short domains within the variable region of the light chain (residues 32, 50, 91-96) , which determine high affinity binding to antigen, have been deliberately mutagenized using partially degenerate primers to create a synthetic library with enormous diversity (Pini et al . , 1998, J. Biol. Chem. 273:21769-21776).
- kits for cloning antibodies into phagemids for expression in E. coli are commercially available.
- that kit and the protocols set forth therein are used to clone selected antibodies and test them in vi tro for their ability to neutralize the target pathogen (s).
- the cloned antibodies are then adapted for transformation and expression in the selected probiotic bacterium.
- genes encoding recombinant antibodies isolated in the first rounds of selection are deliberately subjected to random mutagenesis using degenerate primers to both the heavy chain and light chain antigen binding domains to isolate mutant variants with enhanced binding affinities for neutralizing sites on the pathogen of interest (Pini et al., 1998, J. Biol. Chem. 273:21769-21776).
- the sequence of the antibody protein may be deliberately altered to increase the affinity of binding to the neutralizing sites on the pathogen and/or stability in the GI tract.
- a residue within the linker sequence between the V H and V L domains is mutagenized to substitute a cysteine residue in order to enable the formation of disulfide bonds between rAb monomers to yield dimeric rAbs with increased binding affinity.
- codons within protease digestion sites are changed to structurally neutral amino acids to eliminate the digestion site. In this embodiment, if the site occurs within one of the known antigen recognition domains on the recombinant antibody, then mutagenesis is combined with re-selection to identify variants that have lost the protease site and have retained high affinity antigen binding.
- Antibodies immunologically specific for selected pathogens can also be administered in combination with the recombinant probiotic bacteria expressing the antibodies. These antibodies may be isolated, or may be administered while still inside the antibody-expressing cell. The isolated antibodies may be secreted by the recombinant probiotic organism or may be purified natural or recombinant antibodies. The administration of antibodies with the recombinant probiotic bacteria expressing antibodies has the advantage of establishing immune protection immediately, while the probiotic bacteria establish themselves in the gastrointestinal tract and begin to secrete recombinant antibodies.
- Probiotic bacteria suitable for the present invention include any non pathogenic, preferably physiologically beneficial, bacteria that colonize or are otherwise associated with or resident in the gastrointestinal tract of the selected subject animal or human.
- these bacteria are species of the genus Lactobacill us .
- other genera may be utilized, including, but not limited to: Lactococcus, Bifidobacteria, Eubacteria and non-pathogenic strains of Escheri chia coli (see Gibson and Roberfroid, J. Nutrition 125: 1401-1412, 1995) .
- Non-pathogenic Escheri chia coli strains of particular interest include, but are not limited to, E. coli F18 (Cohen et al . , 1983, Infect. Immun. 40:62-69; Myhal et al . , 1982, Eur . J. Clin. Microbiol. 1:186-192), E. coli strain Nissle 1917 ⁇ E. coli DSM 6601, Mutafluor®) (Lodinova- adnikova and Sonnenborn, 1997, Biol. Neonate 1:224-232, incorporated by reference herein) .
- probiotic strain (s) may be determined by a combination of factors, including the normal site of infection for a given pathogen and the normal site for colonization of the antibody-producing bacteria.
- rotavirus typically infects GI epithelium in the last 20-30 % of the GI tract.
- One strategy for neutralizing rotavirus infection would include feeding a mixture of E.
- Probiotic bacterial strains suitable for delivering presynthesized antibody are strains that do not secrete the recombinant antibodies, but rather sequester them inside the cell membrane or wall.
- Such strains include, but are not limited to, laboratory strains of E. coli that have been derived from the original probiotic strain E. coli K12. These laboratory strains of E. coli , such as HB2151, are advantageously selected for their weakened cell walls. While not limiting the function of this embodiment to one mode, it is contemplated that these strains of E. coli expressing at least one recombinant antibody will lyse in the upper GI tract when exposed to the normal bile salts. In lysing, these cells will spill their contents of recombinant antibody into the GI lumen where it will mix with other lumenal contents. This embodiment provides an inexpensive way to deliver pure recombinant antibody to the upper GI tract.
- Lactobacilli are a large and diverse group of Gram-positive bacilli that are common components of the normal indigenous flora of humans and other animals. Lactobacilli are considered "'health promoting," but in any event are rarely pathogenic, making them good candidates for use in the present invention. Indeed, Lactobacilli have been exploited recently as vaccine delivery vehicles, i.e. expressing antigens in the GI tract of immune-functional individuals for purposes of eliciting an immune response (see, e.g., Rush et al . , Chapter 6 in Gram-Positive Bacteria as Vaccine Vehicles for Mucosal Immunization, (G. Pozzi & J.M. Wells, eds .
- Lactobacillus Different strains and species of Lactobacillus are differentially capable of colonizing or becoming otherwise associated with the GI tract of a particular animal.
- Two approaches can be used in selecting appropriate strains for delivery of antibodies to a particular animal species (including humans) : (1) selection of strains known to be capable of colonizing mucosal surfaces of the animal (e.g., Lactobacill us GG is known to colonize the human GI tract) ; and/or (2) selection of strains naturally found in foods, which may have limited interactions with the host GI tract, but nevertheless may inhabit the GI tract for significant periods of time.
- the fate of viable Lactobacill us cells within the GI system of mammals depends on a number of variables. At one extreme, the bacterial cells simply mix with the undigested fiber of ingested food and move along the GI system secreting antibody into the mucosal matrix that covers the inner surface of the GI epithelium. In this situation there is little colonization by the Lactobacill us cells. At the opposite extreme, cells will find host sites within the mucosal matrix, stay there and replicate (i.e., w colonize" ) , and continue to secrete antibody into the mucosal matrix around them. The factors that determine the ability of cells to colonize or merely populate sites within the GI system are not fully understood.
- Some parameters that affect the ability of probiotic bacteria to colonize include: the pH of the particular GI site (acidophilus means "acid lover” meaning these strains can accommodate the low pH of the stomach and duodenum) ; the oxygen content of the site; the strain of bacteria; and the ability to compete for nutrients with other types of bacteria that are encountered on the mucosal surface of GI epithelium.
- selection of appropriate strains can be made on the basis of how long such secretion is desired in the individual undergoing the treatment.
- combinations of different strains, some transient and others colonizing can be used to provide short and long-term immune protection.
- Lactobacill us species have been demonstrated amenable to transformation and expression/secretion of recombinant proteins.
- Lactobacilli can be genetically modified by way of two mechanisms: (1) via introduction of an ectopic plasmid carrying a foreign gene; or (2) via stable integration of a foreign gene into the genome.
- One advantage to this latter approach is that it avoids potential loss of the foreign gene, which can result from plasmid shedding during expansion of the bacterial cultures.
- the potential lower expression associated with stable integration of the foreign gene could be offset by the more stable retention of that gene and resulting ability of the bacteria to express and secrete recombinant antibodies for an extended period of time.
- Lactobacill us species There are numerous examples in the art of cloning and expression vectors designed for use in Lactobacill us species. Moreover, the art describes the successful introduction and expression of foreign genetic material in a variety of Lactobacill us species, including L . casei , L . braevi s, L . plantarum, L . paracasei , L . acidophil us, L . fermentum and L . zeae, among others (Rush et al . , 1997, supra ; Rush et al . , Microbiol. Biotechnol. 47: 537-542, 1997; Hols et al . , Microbiology 143: 2733- 2741, 1997).
- Example 3 describes vector design and a protocol for transformation of an L . gasseri strain that colonizes the murine upper GI tract.
- This protocol follows standard protocols for transformation of Lactobacill us by electroporation (see, e.g., Aukrust et al . , Chapter 20 in Methods in Molecular Biology, Vol. 47, (J.A. Nickoloff, ed.), Humana Press Inc., Totowa, N.J.).
- the stable integration of foreign genes into the Lactobacill us genome via the temperate phage mv4 has also been described (Dupont et al., J. Bact . 177 : 586- 595, 1995; Avuray et al . , J. Bact.
- the vectors presently available in the art for transforming Lactobacill us were not designed for consumption by humans or animals.
- most of the vectors utilize antibiotic resistance as a selection means. Since it is undesirable to introduce antibiotic resistance into an animal or human patient, the currently available vectors should be modified to comprise a different selection means, such as a color indicator. Selection means that do not rely on antibiotic resistance are known in the art and are available.
- the recombinant antibody-expressing probiotic bacteria are produced, they are used to protect against invasion by the selected pathogen in neonates or other individuals requiring such treatment.
- the mode of administration is by oral or nasal injection, or by feeding (alone or incorporated into the subject's feed or food) .
- the bacteria preferably are introduced into the GI tract at birth, and thereafter periodically until the infant's immune system becomes functional.
- the Lactobacill us acidophil us that is presently widely available commercially is sold as gel capsules containing a lyop ilized mixture of bacterial cells and a solid support such as mannitol.
- the lyophilized cells When the gel capsule is ingested with liquid, the lyophilized cells are re-hydrated and become viable, clonogenic bacteria.
- Lactobacill us cells are added to the neonate' s milk substitute by sprinkling in the powdered, lyophilized preparation. The re-hydrated, viable Lactobacill us cells will then populate and/or colonize at sites throughout the upper and lower gastrointestinal system, and by constitutively secreting recombinant antibody, provide a blanket of protection against the pertinent pathogens.
- the bacteria should be administered as soon as, or prior to (if possible), immunosuppression or exposure to extreme doses of a GI pathogen occurs.
- probiotic strains of the invention that populate the GI tract can be continuously consumed as a gel capsule for as long as a potential threat remains. After consumption of such capsules is terminated, the probiotic cells are slowly diluted away from the GI tract.
- the probiotic bacteria of the invention are used to abruptly stop the widespread morbidity associated with such public health infections rather than to allow an extended, slow disappearance of infections as the pathogen is brought under control by various means, if any.
- the method of treatment of the invention is particularly important as no chemotherapy is currently available.
- distribution and consumption of probiotic bacteria secreting the appropriate antibodies can provide immediate immune coverage for the population, thereby quickly reducing the number of infectable hosts and greatly accelerating the disappearance of the metropolitan epidemic.
- the composition of the invention may be formulated in dosage unit form for ease of administration and uniformity of dosage.
- Dosage unit form refers to a physically discrete unit of the composition appropriate for the patient undergoing treatment. Each dosage should contain a quantity of active ingredient calculated to produce the desired effect in association with the selected pharmaceutical carrier. Procedures for determining the appropriate dosage unit are well known to those skilled in the art
- the composition comprising a probiotic microorganism expressing the antibody or antibodies of choice preferably is administered orally, with or without supplementary antibodies.
- the bacteria and optional antibodies may be hydrated or lyophilized.
- Several options exist for formulating these boluses including tablets, capsules, solutions, syrups, elixirs, suspensions, magmas, gels and powders.
- the composition may also include diluents, disintegrants, desiccants, coatings and colorants. Enteric coatings may be used to delay dissolution of the tablet until it has passed into the intestine.
- the composition of the invention may further comprise food products.
- the most common method of administering the composition of the invention will comprise oral dosing of a composition comprising lyophilized bacteria, lactose or maltodextrin as a carrier/filler and stir the tasteless powder into milk substitute (livestock) or formula (humans) that is being fed to the neonates multiple times each day.
- a composition comprising lyophilized bacteria, lactose or maltodextrin as a carrier/filler and stir the tasteless powder into milk substitute (livestock) or formula (humans) that is being fed to the neonates multiple times each day.
- milk substitute livestock
- formula humans
- gel capsules or compressed tablets containing the same mixture of lyophilized bacteria and carrier/filler used in neonates is contemplated as the most efficient way to consume the probiotic bacteria. Examples in which lyophilized probiotic bacteria are administered as described above are well known in the art and are also commonly used by health food consumers in today's marketplace.
- the probiotic microorganism composition is administered to a neonate over the period of time during which the animals are immunologically at-risk.
- a bolus comprising 3 X 10 s - 40 X 10 9 colony forming units is be administered two times a day, for up to eight weeks.
- antibodies may be added to the neonate bolus at a concentration between 0.1 mg - 25.0 mg/kg body weight/day, depending upon the relative binding affinity of the respective antibodies.
- the probiotic bacterial composition is administered to an adult in a bolus comprising 12 X 10 9 - 80 X 10 9 colony forming units, three times a day for at least ten days.
- the actual duration of administration will be largely determined by the duration of the external pathogen threat.
- the composition of the probiotic material administered to adults will be the same as previously described for neonates, and the method by which it is administered will include gel capsules, compressed capsules and dispersal in foods.
- the lyophilized bacteria preparations may be prepared at up to 10 10 colony forming units per gram and then diluted out with filler/carriers like maltodextrin to simplify handling.
- a murine hybridoma cell line (#159) expressing a rotavirus serotype G3-neutralizing monoclonal antibody was obtained as a gift from H.B. Greenberg, Stanford University.
- a culture of the #159 cell line containing ⁇ 5 x 10 6 viable cells was prepared.
- Messenger RNA was isolated from the cultured cells using the QuickPrep® mRNA purification kit (Pharmacia, Piscataway N.J.) according to the manufacturer's instructions. The RNA was ethanol-precipitated, resuspended in 20 ⁇ l RNAse free water and heated to remove any secondary structure. First strand cDNA synthesis was then performed according to the manufacturer' s instructions.
- the first strand antibody cDNA was used as a template for PCR amplification to generate suitable quantities of antibody heavy and light chain DNA for cloning. This was accomplished by standard PCR protocols (as set forth in the manufacturer's instructions), using primers specifically hybridizing to appropriate heavy chain and light chain-encoding DNA.
- the amplified heavy and light chain PCR fragments were separated from other components of the mixture by preparative agarose gel electrophoresis, followed by excision of the separated bands and elution of the fragments from the agarose. The purified products were then gel quantified.
- the antibody heavy and light chain DNA were joined into a single chain with a linker DNA segment provided by the manufacturer.
- the resultant combined DNA segment (referred to in the manufacturer's instructions as the ScFv DNA) was amplified by PCR, using primers containing either Notl or Sfil restriction sites.
- the final product was separated from other components of the PCR mixture by centrifugation in a MicroSpin column, after which the ScFv DNA segment was quantitated.
- the ScFv DNA was subjected to digestion with Notl and Sfil for ligation into a similarly digested phagemid vector, pCANTAB 5E, provided with the kit.
- the phagemid displays the recombinant antibody domain because it is fused to the external, filamentous gene 3 protein.
- Competent E. coli TGI cells were then transformed with the pCANTAB 5E vector containing the antibody ScFv insert.
- Two clones, clone 11 and clone 22, were selected for further study.
- the ⁇ 750 bp Sfil - Notl rAb inserts of clone 11 (SEQ ID NO:l; Fig. 1) and clone 22 (SEQ ID NO: 2; Fig. 2) were sequenced.
- TGI cells contain a stop-codon suppressor that causes a portion of the recombinant antibody to remain attached to the phage. Recombinant phage were rescued from the transformed E. coli according to the manufacturer's
- Immunoblotting showed the level of recombinant antibody in the media from E . coli clones 11 and 22, and a purified fraction of rAb from an anti-E immunoaffinity column (Fig. 3) .
- Cultures of HB2131 cells were induced with 1 mM IPTG for 4 hours. Cells were pelleted by centrifugation, and 1 ml media aliquots were precipitated with 10% TCA on ice. Proteins were neutralized with Tris base, dissolved in SDS sample buffer and electrophoresed on a 4-12% polyacrylamide gel. Proteins were transferred to a PVDF membrane and probed with an anti-E tag antibody conjugated with horseradish peroxidase. Color development of bands was done using ABTS reagents.
- Fig. 3 one ml of bacterial media is shown to contain about 0.3 ug of recombinant antibody.
- this culture there were ⁇ 2 X 10 9 bacteria/ml which extrapolates to 0.2 pg recombinant antibody produced per cell per hour.
- Recombinant phage were tested for expression of the anti-rotavirus antibody by immunological interaction with intact rotavirus or with the epitope for which the urine Mab is specific, if it is known. Following this confirmation, E. coli may be reinfected with the phage clones. The E.
- coli strain HB2151 (which does not contain the stop codon suppressor) was used for the purpose of producing soluble recombinant anti-rotavirus antibodies, in accordance with the manufacturer's instructions. Soluble rAb was purified on an anti-E tag immunoaffinity column as per the manufacturers instructions (Fig. 4) . Fifty ml of bacterial media from IPTG-induced clone 11 cells was applied to column; column was washed and then eluted with 0.1 M glycine (pH 3.0) .
- MA-104 cells which are host cells that allow replication of RRV2-1 rotavirus in tissue culture.
- the MA-104 cells are infected with the RRV2-1 rotavirus, letting the lytic viral expansion occur in the tissue culture dishes, and then harvesting the virus particle-laden media supernates.
- the virus-containing media is subjected to both fluorocarbon extraction and sucrose density centrifugation to yield highly concentrated viral stocks which are then titred to determine the number of infectious viral particles per ml using MA-104 monolayer cultures in a standard plaque-forming assay. After a week in culture, these plaques are scored by staining the monolayer with crystal violet and scoring the number of clear plaques formed. The number of clear plaques equals the number of infectious virus particles applied to the plate. Viral stocks typically exceed 1 x 10 9 plaque- forming units (pfu) per ml.
- the titered tissue culture supernates are used for at least four purposes.
- the virus particles are adsorbed on to the bottom of a multiwell plate, and then media is added that contains individual clones of E. coli cells that are known to be making recombinant antibody.
- the recombinant antibody is still fused to the end of a phage protein that is extended from the surface of the E. coli cell.
- the adsorbed rotavirus i.e., panning, one can also recover the E. coli cell and the recombinant gene that encodes the recombinant antibody.
- a more refined manner is employed for selecting soluble, recombinant antibodies that have desirable characteristics for the binding of rotavirus, now in suspension rather than adsorbed to a plastic surface.
- rotavirus particles that have been detectably labeled e.g., biotinylated
- the conditions of the binding assay can be varied to select for recombinant antibodies that have particular binding characteristics that might be desirable when they are secreted from Lactobacillus cells in the lumen of an animal's intestine. This might include, for instance, the ability to bind rotavirus or the K99 antigen of ETEC E.
- coli at a reduced pH representative of food leaving the stomach. Panning can actually be done in the presence of dilutions of previously sterilized GI lumenal contents to accurately reflect the conditions under which antigen-recombinant antibody binding occurs. Binding of soluble, recombinant antibody to biotinylated rotavirus particles can be demonstrated by adding avidin coated beads to bind the biotinylated rotavirus, and pelleting. The resuspended beads are incubated with, e.g., a fluorescein-labeled anti-mouse antibody.
- the fluorescein-labeled secondary antibody will also bind and this is monitored using a standard 96 well fluorescence monitor.
- the neutralizing ability of recombinant antibodies can be screened by adding known numbers of plaque-forming units from RRV stocks to MA-104 monolayers to achieve a known number of clear plaques per tissue culture well. Dilutions of individual recombinant antibodies are preincubated with the titered virus supernates prior to adding the virus to MA-104 supernates . A reduction in the number of clear plaques is indicative of the ability of the recombinant antibody to neutralize binding and infection of natural host cells.
- test cells such as MA-104 cells are examined. These results are used to infer the neutralizing effect of the antibodies in normal GI epithelial cells of host organisms.
- normal host organisms i.e., those animals that develop severe GI distress when infected, include at least mice, humans and monkeys.
- bacteria first laboratory and probiotic strains of E.
- mice HB2151, F-18, Nissle 1917
- Lactobacill us e.g., Lactobacill us gasseri which are known to colonize in mice
- virus-laden supernate typically 10 7 pfus
- Mice are scored for the presence of a fulminant RRV infection by gently pressing the abdomen and examining the anal region for the presence of yellow watery stool or for the presence of yellow stool in the last 5 cm of the colon.
- the anti-rotavirus-encoding SvFc DNA described in Example 1 is used to produce a plasmid for transformation and expression in Lactobacill us .
- This plasmid is a derivative of the plasmid pZN17, which contains a broad host-range Lactococcus lacti s plasmid pSH71 replicon and is a low copy number plasmid both in E. coli and Lactococcus lactis .
- the pCMR102 plasmid further comprises a synthetic derivative, EZZ, of the protein A gene from Stapl ococcus aureus .
- the pCMR102 plasmid has been shown to direct production and export of a heterologous protein in several Lactobacill us species (Rush et al . , 1996, supra ) .
- the MOMP VD4-encoding segment of pCMR102 is excised from the plasmid by restriction digestion with EcoRL and Pstl, and replaced with the rotavirus antibody- encoding ScFv DNA, which has been end-modified to contain the appropriate restriction sites.
- the new plasmid comprises a DNA segment encoding an in-frame fusion protein of the anti-rotavirus antibody and the EZZ protein.
- the purified plasmid DNA is digested with appropriate restriction enzymes to remove an intact DNA cassette that contains 5' and 3' regulatory sequences and the coding sequence for both the recombinant antibody, as well as a gene product that will enable colorimetric or immune screening for bacterial colonies that are synthesizing the encoded gene products.
- the expression cassette is electroporated under the previously optimized conditions into the appropriate strain of log-phase growing probiotic host cells.
- the cells are then plated under non-selective conditions, and a large number of probiotic bacterial colonies are screened to detect colonies that are (1) synthesizing and secreting the recombinant antibody and/or (2) expressing the originally attached gene that would enable colorimetric screening.
- the above-mentioned latter step of transferring in a DNA fragment to the bacterial cells and then growing the cells to enable integration of the gene expression cassette into a neutral or favored site within the genome of the selected probiotic bacterium is done for two reasons : (1) so that the bacteria will have no drug resistance genes in them when they are released and consumed as a product by otherwise healthy individuals, and (2) so that the likelihood of shedding the recombinant antibody gene from the bacterial genome is greatly reduced or eliminated, as compared to placement of the gene on an ectopic plasmid.
- Lactobacill us species are amenable to transformation by electroporation.
- this example we describe a protocol devised for the transformation of Lactobacill us gasseri .
- MRS broth 10.0 g peptone, 8.0 g meat extract, 4.0 g yeast extract, 20.0 g glucose, 1 mL monooleate (Tween
- MRS plates MRS broth solidified with 1.5% agar.
- MRSSM MRS with 0.5 M Sucrose, 0.1 M MgCl 2 .
- DNA Dissolve plasmid pGK12 in TE (lOmM Tris-HCl, 1 mM EDTA, pH 7.5) to 0.10-1.0 ⁇ g/ ⁇ L. Ligation mixtures should be ethanol precipitated and washed, then dissolved in TE before electroporation. Methods :
- the DNA in a volume 1/20 of the cell suspension volume was added immediately before electroporation.
- the mixture was transferred to an ice cold electroporation cuvette with a 2-mm electrode gap.
- Different electric pulses were delivered as shown in Table 1 below.
- MRSSM was added to the cuvette and the resulting diluted cell suspension transferred to a microfuge tube and incubated at 30 C for 2 hrs . Undiluted and serial dilutions of the cell suspension were spread on MRS plates containing appropriate selection ingredients (e.g., antibiotics, color indicators). Plates were incubated at 30 C for up to 3 days, to allow for growth of colonies of transformed cells.
- appropriate selection ingredients e.g., antibiotics, color indicators
- Oral administration of the rotavirus monoclonal antibody M159 prevents the development of the symptoms of diarrhea in mouse.
- a feeding tube was used to administer a gastric bolus to 7 day old mouse pups, followed by an oral rotavirus challenge dose.
- a gastric bolus containing 50 ⁇ g to less than 1 ⁇ g of M159 rotavirus antibody gave complete protection against the oral dose of rotavirus (7.5 X 10 6 pfus) that immediately followed (Fig. 5) .
- the unprotected mouse pups exhibited 100% infection at three days.
- a gastric bolus of 25 ⁇ g M159 antibody gave complete protection against an oral rotavirus challenge (7.5 X 10 6 pfus) administered up to 24 hours later, while control mouse pups exhibited 100% infection at three days (Fig. 6) .
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99938901A EP1100950A4 (en) | 1998-07-30 | 1999-07-29 | Gastrointestinal bacterial antibody factories |
IL14114299A IL141142A0 (en) | 1998-07-30 | 1999-07-29 | Gastrointestinal bacterial antibody factories |
CA002338001A CA2338001A1 (en) | 1998-07-30 | 1999-07-29 | Gastrointestinal bacterial antibody factories |
AU53285/99A AU5328599A (en) | 1998-07-30 | 1999-07-29 | Gastrointestinal bacterial antibody factories |
JP2000562546A JP2002521494A (en) | 1998-07-30 | 1999-07-29 | Gastrointestinal bacterial antibody factory |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9469798P | 1998-07-30 | 1998-07-30 | |
US60/094,697 | 1998-07-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000006764A1 true WO2000006764A1 (en) | 2000-02-10 |
Family
ID=22246653
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/017296 WO2000006764A1 (en) | 1998-07-30 | 1999-07-29 | Gastrointestinal bacterial antibody factories |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1100950A4 (en) |
JP (1) | JP2002521494A (en) |
AU (1) | AU5328599A (en) |
CA (1) | CA2338001A1 (en) |
IL (1) | IL141142A0 (en) |
WO (1) | WO2000006764A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007019901A1 (en) * | 2005-08-19 | 2007-02-22 | Unilever N.V. | Food products comprising probiotic micro-organisms and antibodies |
WO2008071751A1 (en) * | 2006-12-14 | 2008-06-19 | Actogenix N.V. | Delivery of binding molecules to induce immunomodulation |
US8105592B2 (en) | 2004-11-25 | 2012-01-31 | Vhsquared Limited | Heavy chain and single domain antibodies |
WO2012141540A2 (en) * | 2011-04-13 | 2012-10-18 | 씨제이제일제당 (주) | Novel isolated lactobacillus fermentum strain having viral infection inhibitory activity |
EP2873726A4 (en) * | 2012-07-13 | 2016-03-09 | Teikyo Heisei University | Antitumor agent, marker for tumor detection, and oral vaccine agent |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2670882C9 (en) * | 2012-07-20 | 2018-12-11 | Превтек Майкробиа Инк. | Non-pathogenic f18 escherichia coli strain and use thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4571385A (en) * | 1983-06-27 | 1986-02-18 | The United States Of America As Represented By The Department Of Health And Human Services | Genetic reassortment of rotaviruses for production of vaccines and vaccine precursors |
US4950595A (en) * | 1984-09-28 | 1990-08-21 | Teijin Limited | Mouse-human hybridoma which produces antivirus-human antibody, process for preparation thereof, and antivirus-human monoclonal antibody |
US4956452A (en) * | 1987-06-14 | 1990-09-11 | The University Of Maryland | Monoclonal antibody which neutralizes multiple strains of infectious bursal disease virus |
US5531988A (en) * | 1994-10-28 | 1996-07-02 | Metagenics, Inc. | Bacteria and immunoglobulin-containing composition for human gastrointestinal health |
US5637677A (en) * | 1987-07-16 | 1997-06-10 | The Trustees Of The University Of Pennsylvania | Biologically active compounds and methods of constructing and using the same |
US5733540A (en) * | 1995-03-08 | 1998-03-31 | Lee; Peter Poon-Hang | Protection from viral infection via colonization of mucosal membranes with genetically modified bacteria |
US5895758A (en) * | 1997-06-10 | 1999-04-20 | Bio-Energy Systems | Strain of lactobacillus Plantarum |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994021284A1 (en) * | 1993-03-15 | 1994-09-29 | Pharma Pacific Pty. Ltd. | Therapeutic formulation and method |
AUPN698495A0 (en) * | 1995-12-06 | 1996-01-04 | Pharma Pacific Pty Ltd | Improved therapeutic formulation and method |
-
1999
- 1999-07-29 AU AU53285/99A patent/AU5328599A/en not_active Abandoned
- 1999-07-29 EP EP99938901A patent/EP1100950A4/en not_active Withdrawn
- 1999-07-29 IL IL14114299A patent/IL141142A0/en unknown
- 1999-07-29 CA CA002338001A patent/CA2338001A1/en not_active Abandoned
- 1999-07-29 JP JP2000562546A patent/JP2002521494A/en active Pending
- 1999-07-29 WO PCT/US1999/017296 patent/WO2000006764A1/en not_active Application Discontinuation
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4571385A (en) * | 1983-06-27 | 1986-02-18 | The United States Of America As Represented By The Department Of Health And Human Services | Genetic reassortment of rotaviruses for production of vaccines and vaccine precursors |
US4950595A (en) * | 1984-09-28 | 1990-08-21 | Teijin Limited | Mouse-human hybridoma which produces antivirus-human antibody, process for preparation thereof, and antivirus-human monoclonal antibody |
US4956452A (en) * | 1987-06-14 | 1990-09-11 | The University Of Maryland | Monoclonal antibody which neutralizes multiple strains of infectious bursal disease virus |
US5637677A (en) * | 1987-07-16 | 1997-06-10 | The Trustees Of The University Of Pennsylvania | Biologically active compounds and methods of constructing and using the same |
US5531988A (en) * | 1994-10-28 | 1996-07-02 | Metagenics, Inc. | Bacteria and immunoglobulin-containing composition for human gastrointestinal health |
US5733540A (en) * | 1995-03-08 | 1998-03-31 | Lee; Peter Poon-Hang | Protection from viral infection via colonization of mucosal membranes with genetically modified bacteria |
US5895758A (en) * | 1997-06-10 | 1999-04-20 | Bio-Energy Systems | Strain of lactobacillus Plantarum |
Non-Patent Citations (1)
Title |
---|
See also references of EP1100950A4 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8105592B2 (en) | 2004-11-25 | 2012-01-31 | Vhsquared Limited | Heavy chain and single domain antibodies |
WO2007019901A1 (en) * | 2005-08-19 | 2007-02-22 | Unilever N.V. | Food products comprising probiotic micro-organisms and antibodies |
WO2008071751A1 (en) * | 2006-12-14 | 2008-06-19 | Actogenix N.V. | Delivery of binding molecules to induce immunomodulation |
WO2012141540A2 (en) * | 2011-04-13 | 2012-10-18 | 씨제이제일제당 (주) | Novel isolated lactobacillus fermentum strain having viral infection inhibitory activity |
WO2012141540A3 (en) * | 2011-04-13 | 2013-01-10 | 씨제이제일제당 (주) | Novel isolated lactobacillus fermentum strain having viral infection inhibitory activity |
EP2873726A4 (en) * | 2012-07-13 | 2016-03-09 | Teikyo Heisei University | Antitumor agent, marker for tumor detection, and oral vaccine agent |
Also Published As
Publication number | Publication date |
---|---|
JP2002521494A (en) | 2002-07-16 |
IL141142A0 (en) | 2002-02-10 |
AU5328599A (en) | 2000-02-21 |
EP1100950A4 (en) | 2002-10-16 |
CA2338001A1 (en) | 2000-02-10 |
EP1100950A1 (en) | 2001-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9017662B2 (en) | Anti-TNF alpha producing lactic acid bacteria for the treatment of chronic enterocolitis | |
KR20170121291A (en) | Engineered bacteria to treat diseases that benefit from reduced intestinal inflammation and / or enhanced intestinal mucosal barriers | |
US20220127628A1 (en) | A genetically modified lactobacillus and uses thereof | |
EP2273998A2 (en) | Methods and materials for gastrointestinal delivery of pathogen/toxin binding agents | |
CA2438833A1 (en) | Lactic acid bacteria as agents for treating and preventing allergy | |
US20210030814A1 (en) | Compositions and methods for treating or preventing intestinal paracellular permeability | |
Aliramaei et al. | Expression of Helicobacter pylori CagL gene in Lactococcus lactis MG1363 and evaluation of its immunogenicity as an oral vaccine in mice | |
US11839649B2 (en) | Compositions comprising recombinant probiotic bacteria and methods of use thereof | |
WO2000006764A1 (en) | Gastrointestinal bacterial antibody factories | |
US20220265731A1 (en) | Modified escherichia coli strain nissle and treatment of gastrointestinal disorder | |
CN114341165A (en) | Non-parenteral therapy delivery platform for arthrospira platensis | |
KR102100503B1 (en) | Vaccin compsosition for preventing or treating porcine pathogenic colibacillosis comprising ghost enterotoxigenic Escherichia coli as effective componet | |
US20230092431A1 (en) | Bacteria engineered to treat disorders in which oxalate is detrimental | |
KR100933090B1 (en) | Adhesive fusion protein and immunoadjuvant for preventing or treating diarrhea in livestock | |
KR20230111815A (en) | Manufacturing method of single domain vhh antibody for preventing or treating early mortality syndrome | |
KR20210156804A (en) | Salmonella strain for treating cancer and use thereof | |
WO2022221273A1 (en) | Bacteria engineered to secrete active proteins | |
KR20140117787A (en) | Ghost vaccine composition containing Ghost Salmonella mutants for preventing pathogenic colibacillosis and salmonellosis | |
CN116555311A (en) | Escherichia coli Nissle1917 engineering bacterium over-expressing mcmA gene, construction method and application thereof | |
Almdni | Recombinant antibodies against Clostridium difficile Toxin A |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 53285/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999938901 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 141142 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2338001 Country of ref document: CA Ref country code: CA Ref document number: 2338001 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 562546 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09744707 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1999938901 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999938901 Country of ref document: EP |